Abbonarsi

Newly emerging synthetic cannabinoids and novel modes of use of benzodiazepines in prisons: An update from the Scottish Prisons Non-Judicial Seizures Drug Monitoring Project - 15/08/22

Doi : 10.1016/j.toxac.2022.06.253 
Caitlyn Norman 1, , Robert Reid 1, Kevin Hill 2, Fiona Cruickshanks 2, Niamh Nic Daeid 1
1 Leverhulme research centre for forensic science, University of Dundee, Dundee, United Kingdom 
2 Public protection unit, Scottish prison service, Edinburgh, United Kingdom 

Corresponding author.

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

Riassunto

Aim

In July 2021, the Chinese government implemented analogue controls for synthetic cannabinoid receptor agonists (SCRAs) covering the most popular compounds on the market at the time. International legislation is one of the main driving forces of market change and prisons can act as an early warning system for the emergence of new psychoactive substances (NPS) and novel modes of use. This study reports the latest synthetic cannabinoid receptor agonists (SCRAs) and benzodiazepines to emerge in the Scottish prisons following the international controls and the new modes of use of benzodiazepines that have emerged.

Method

Since the start of the Scottish Prisons Non-Judicial Seizures Drug Monitoring Project in September 2018, over 1600 individual samples from over 1200 unattributable suspected drug seizures have been tested. Samples included infused paper and card, tablets, powders, infused clothing, and blotters. Qualitative screening of seized samples suspected to contain controlled substances was carried out using gas chromatography-mass spectrometry (GC-MS) with verification by comparison to reference standards and/or orthogonal analysis by ultra-performance liquid chromatography with quadrupole time of flight mass spectrometry (UPLC-QToF-MS) if reference standards were not available.

Results

Following the enactment of the Chinese analogue controls for SCRAs in July 2021, seven new (or re-emerged) compounds have been detected in the Scottish prisons that circumvent this legislation, including 5F-3,5-AB-PFUPPYCA and 5,3-ADB-4en-PFUPPYCA in Q3 2021; BZO-HEXOXIZID (MDA-19), MDMB-5Br-INACA, ADB-5Br-INACA, and ADB-FUBIATA in Q4 2021; and CH-PIATA in Q1 2022. However, despite being controlled by this Chinese legislation, ADB-BUTINACA has remained the most common SCRA detected within the Scottish Prisons, appearing in over 66% of all SCRA samples since its first detection in Q1 2021. This could be due to a supply stockpile; production in other countries, such as India; or a new “self-assembly” product where people buy a pre-synthesis product, such as ADB-5Br-INACA, in a set with additional chemicals and instructions to complete the synthesis themselves.

Etizolam was the most commonly detected benzodiazepine, appearing in over 81% of all benzodiazepine samples since Q1 2021, despite its international control in March 2020. Once again, this could be due to a supply stockpile or production in other countries without an etizolam control, such as India. Although there may be other routes of supply for etizolam, other benzodiazepines have emerged that are not internationally controlled, including flubromazepam and bromazolam. Flubromazepam emerged in Q3 2021 and since then has been detected in over 35% of benzodiazepine samples. In Q4 2020, benzodiazepines began to be detected in infused card and paper, a method previously almost exclusively used with SCRAs. By Q3 2021, card and paper became the most common matrix for benzodiazepines in the Scottish prisons. Benzodiazepine-infused cards and papers are often boiled in kettles and the liquid ingested; however, they are also vaped. There is little, if any, published information to date regarding the effects or harms of smoking or vaping benzodiazepines.

Conclusion

Near-real time analysis of seized samples is vital for the rapid detection of new NPS compounds emerging in prisons and the general population in response to changes in international legislation. Compounds may have different potency and/or effects depending on the mode of use, so it is important for intelligence around modes of use to be gathered and investigated.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


© 2022  Pubblicato da Elsevier Masson SAS.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 34 - N° 3S

P. S150 - Settembre 2022 Ritorno al numero
Articolo precedente Articolo precedente
  • Fatal Intoxication with a mixture of para-methoxyamphetamine, N-ethylpentylone, and ketamine
  • Kanako Noritake, Kanju Saka, Kana Unuma, Takeshi Funakoshi, Ruri Kikura-Hanajiri, Yohsuke Makino, Hirotaro Iwase, Koichi Uemura
| Articolo seguente Articolo seguente
  • Prevalence of alcohol among drivers, riders and pedestrians injured in road traffic crashes in Cameroon: A cross-sectional study
  • Yannick Oyono, Hallvard Gjerde, Tara Kelley-Baker, Emmanuel Asongalem Acha, Boris Arnaud Kouomogne Nteungue, Carolle Yanique Tayimetha, Olivier Djouyep Momo, Claude Patrick Biwole Biwole, David Owandja Mekolo, Valerie Ngono, Yaouba Djakari, Johannes G. Ramaekers, Eric Akum Achidi

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.